Steiner G (2007). „Atherosclerosis in type 2 diabetes: a role for fibrate therapy?”. Diab Vasc Dis Res. 4 (4): 368—74. PMID18158710. doi:10.3132/dvdr.2007.067.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). „Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Am J Med. 122 (10): 962.e1—962.e8. PMID19698935. doi:10.1016/j.amjmed.2009.03.030.
Jun M; Foote C; Lv J; et al. (2010). „Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis”. Lancet. 375 (9729): 1875—1884. doi:10.1016/S0140-6736(10)60656-3.CS1 одржавање: Експлицитна употреба et al. (веза)
nih.gov
ncbi.nlm.nih.gov
Steiner G (2007). „Atherosclerosis in type 2 diabetes: a role for fibrate therapy?”. Diab Vasc Dis Res. 4 (4): 368—74. PMID18158710. doi:10.3132/dvdr.2007.067.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). „Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Am J Med. 122 (10): 962.e1—962.e8. PMID19698935. doi:10.1016/j.amjmed.2009.03.030.